FDA Approved: VOXZOGO 0.4MG — Supplemental Application (BioMarin Pharmaceutical Inc.)

View source ↗

Summary

FDA approved BioMarin’s supplemental application to add a 0.4 mg strength of VOXZOGO (vosoritide) for achondroplasia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Achondroplasia

Drugs mentioned

• VOXZOGO (VOSORITIDE)

Snippet

SUPPL AP for VOXZOGO 0.4MG (VOSORITIDE)